Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint…
Author: Medical News Today
American Academy Of Ophthalmology Launches Expanded GetEyeSmart.org, A Trusted Source For Eye Health Information
The American Academy of Ophthalmology (Academy) has launched an expanded and authoritative eye health website to help educate consumers about eye diseases and conditions, vision correction and the preservation of healthy vision across a lifetime…
Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)
Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint…
JPEG For The Mind: How The Brain Compresses Visual Information
Most of us are familiar with the idea of image compression in computers. File extensions like “.jpg” or “.png” signify that millions of pixel values have been compressed into a more efficient format, reducing file size by a factor of 10 or more with li…
JPEG For The Mind: How The Brain Compresses Visual Information
Most of us are familiar with the idea of image compression in computers. File extensions like “.jpg” or “.png” signify that millions of pixel values have been compressed into a more efficient format, reducing file size by a factor of 10 or more with li…
Hi-Tech Pharmacal Receives Final Approval For Levofloxacin Ophthalmic Solution
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced that the US Food and Drug Administration, (FDA) granted final approval for the Company’s Abbreviated New Drug Application, (ANDA) for levofloxacin ophthalmic solu…
Hi-Tech Pharmacal Receives Final Approval For Levofloxacin Ophthalmic Solution
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced that the US Food and Drug Administration, (FDA) granted final approval for the Company’s Abbreviated New Drug Application, (ANDA) for levofloxacin ophthalmic solu…
GP Commissioners Can Take Away Cinderella Status Of Eye Health Says Department Of Health Primary Care Lead
Emerging GP Consortia have the chance to get rid of eye health’s “Cinderella Status” in terms of local health priorities, according to Jill Matthews, National Implementation Director for Primary Care Improvement…
Study Reveals How Omega 3’s Work In Preventing Several Forms Of Blindness
Omega-3 fatty acids – fats commonly found in fish oil – were shown several years ago to prevent retinopathy, a major form of blindness, in a mouse model of the disease…
Advanced Macular Degeneration Is Associated With An Increased Risk Of Bleeding Stroke In Elderly
Older people with late-stage, age-related macular degeneration (AMD) appear to be at increased risk of brain hemorrhage (bleeding stroke), but not stroke caused by brain infarction (blood clot), according to research presented at the American Stroke As…
R-Tech Ueno Initiates A Phase I Clinical Study Of RK-023 For The Treatment Of Hypotrichosis Of The Eyelashes
R-Tech Ueno (JASDAQ:4573) is pleased to announce the initiation of a Phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes(1). The details of the trial are summarized below…
NICE Consults On Dexamethasone Intravitreal Implant For The Treatment Of Macular Oedema Secondary To Retinal Vein Occlusion
In preliminary recommendations published today (8 February) NICE is asking Allergan for more information on its product dexamethasone (Ozurdex) intravitreal implant, for the treatment of macular oedema secondary to retinal vein occlusion (RVO). The mac…
NICE Consults On Dexamethasone Intravitreal Implant For The Treatment Of Macular Oedema Secondary To Retinal Vein Occlusion
In preliminary recommendations published today (8 February) NICE is asking Allergan for more information on its product dexamethasone (Ozurdex) intravitreal implant, for the treatment of macular oedema secondary to retinal vein occlusion (RVO). The mac…
Potential Cause Of Blindness Uncovered
Blindness is prevalent amongst the aging. It affects one in 50 people over 50 and one in five people over 85. The exact cause is unknown, but risk factors include smoking, high blood pressure and having relatives with the condition. Announced this we…
Potential Cause Of Blindness Uncovered
Blindness is prevalent amongst the aging. It affects one in 50 people over 50 and one in five people over 85. The exact cause is unknown, but risk factors include smoking, high blood pressure and having relatives with the condition. Announced this we…
In Age-Related Macular Degeneration, Key Mechanism Identified, 2 Possible Therapies Developed
A team of researchers, led by University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, has discovered a molecular mechanism implicated in geographic atrophy, the major cause of untreatable blindness in the industrialized world. Their article, “DI…
New Insights Into Vision Loss, Australia
A trigger for the most common form of vision loss and blindness in Australia has been discovered thanks to research conducted with help from Australian eye donors…
In Age-Related Macular Degeneration, Key Mechanism Identified, 2 Possible Therapies Developed
A team of researchers, led by University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, has discovered a molecular mechanism implicated in geographic atrophy, the major cause of untreatable blindness in the industrialized world. Their article, “DI…
UK Recognition For Top Queen’s Scientist For Research Into Vascular Stem Cells And Eye Disease
One of Northern Ireland’s leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen’s University…
AMD Geographic Atrophy Clue Raises Therapy Hope For Major Cause Of Blindness
Discovery of a key enzyme mechanism in geographic atrophy, a late stage in “dry type” age-related macular degeneration (AMD), is raising hope of two possible new therapies for a major cause of untreatable blindness in the industrialized world…